Anti-Idiotype Vaccines

  • Sunil K. Chatterjee
  • Malaya Bhattacharya-Chatterjee
  • Kenneth A. Foon
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Active specific immunotherapy (ASI) is an attractive approach to cancer therapy, especially in an adjuvant setting. ASI is intended to boost or induce a host antitumor response, in contrast to passive immunotherapy, where large doses of preformed antitumor antibodies, or T cells with predetermined specificity, are infused. In classical ASI, patients are vaccinated with purified tumor-specific or tumor-associated antigens (TAAs). This approach has a number of major limitations. The tumor antigens are usually weakly immunogenic due to the induction of tolerance. This tolerance can be broken by presentation of the critical epitope in a different molecular environment (1). Secondly, it is difficult to obtain the purified antigen in sufficient quantities for vaccination. Although this limitation can be overcome by the synthesis of well-defined antigens by use of recombinant DNA technology, the recombinant molecule may not resemble the native structure of the protein. Moreover, mass production of nonprotein antigens, such as carbohydrates or lipids, is not possible by recombinant DNA technology. These limitations can be overcome by using an elegant approach to AST, with the use of anti-idiotypic (Id) antibodies.


Mouse Mammary Tumor Virus Keyhole Limpet Hemocyanin Internal Image General Vaccine Active Specific Immunotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Weigle WO. The immune response of rabbits tolerant to bovine serum albumin to the injection of other heterologous serum albumins. J Exp Med 1961; 114:111–125.PubMedCrossRefGoogle Scholar
  2. 2.
    Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) 1974; 125C:373–389.Google Scholar
  3. 3.
    Lindenmann J. Speculations on idiotypes and homobodies. Ann Immunol (Paris) 1973; 124:171–184.Google Scholar
  4. 4.
    Bona CA, Kohler H. Antiidiotypic antibodies and internal images in monoclonal and anti-idiotypic antibodies. In: Ventor JC, Fraser CM, Linstrom J, eds. Monoclonal and anti-idiotypic antibodies: probes for receptor structure and function. New York: Alan R. Liss. 1984:141–149.Google Scholar
  5. 5.
    Bona CA. Internal image concept revisited. Proc Soc Exp Biol Med 1996; 213:32–42.PubMedGoogle Scholar
  6. 6.
    Kennedy RC, Dreesman GR, Butel JS, Lanford RE. Suppression of in vivo tumor formation induced by simian virus 40-transformed cells in mice receiving antiidiotypic antibodies. J Exp Med 1985; 161: 1432–1449.PubMedCrossRefGoogle Scholar
  7. 7.
    Kennedy RC, Zhou EM, Lanford RE, Chanh TC, Bona CA. Possible role of anti-idiotypic antibodies in the induction of tumor immunity. J Clin Invest 1987; 80:1217–1224.PubMedCrossRefGoogle Scholar
  8. 8.
    Nepom GT, Nelson KA, Holbeck SL, Hellstrom I, Hellstrom KE. Induction of immunity to a human tumor marker by in vivo administration of anti-idiotypic antibodies in mice. Proc Natl Acad Sci USA 1984; 81:2864–2867.PubMedCrossRefGoogle Scholar
  9. 9.
    Raychaudhuri S, Saeki Y, Fuji H, Kohler H. Tumor-specific idiotype vaccines. I. Generation and characterization of internal image tumor antigen. J Immunol 1986; 137:1743–1749.PubMedGoogle Scholar
  10. 10.
    Dunn PL, Johnson CA, Styles JM, Pease SS, Dean CJ. Vaccination with syngeneic monoclonal antiidiotype protects against a tumour challenge. Immunology 1987; 60:181–186.PubMedGoogle Scholar
  11. 11.
    Sasaki J, Tamagake T, Narita S, Ahsan CR. Idiotype vaccine for tumor by anti-idiotypic antibody prepared against anti-(bacillus Calmette Guérin) BCG monoclonal antibody. Cancer Immunol Immunother 1990; 31:273–277.PubMedCrossRefGoogle Scholar
  12. 12.
    Minamizuka T, Eto H, Nakata M, Yagita H, Okumura K. Effect of immunization with anti-idiotypic antibody to melanoma antigen on lung metastasis in mice. Nippon Geka Hokan 1992; 61:413–422.PubMedGoogle Scholar
  13. 13.
    Jinnohara T, Tsujisaki M, Sasaki S, Hinoda Y, Taniguchi M, Imai K. Anti-tumor effect of internal image bearing anti-idiotypic monoclonal antibody in relation to GM3 ganglioside. IntJ Cancer 1998; 76:345–353.CrossRefGoogle Scholar
  14. 14.
    Pervin S, Chakraborty M, Bhattacharya-Chatterjee M, Zeytin H, Foon KA, Chatterjee SK. Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. Cancer Res 1997; 57:728–734.PubMedGoogle Scholar
  15. 15.
    Bhattacharya-Chatterjee M, Mukerjee S, Biddle W, Foon KA, Kohler H. Murine monoclonal antiidiotype antibody as a potential network antigen for human carcinoembryonic antigen. J Immunol 1990; 145:2758–2765.PubMedGoogle Scholar
  16. 16.
    Monestier M, Debbas ME, Goldenberg DM. Syngeneic anti-idiotype monoclonal antibodies to murine anticarcinoembryonic antigen monoclonal antibodies. Cancer Res 1989; 49:123–126.PubMedGoogle Scholar
  17. 17.
    Losman MJ, Monestier M, Hansen Hi, Goldenberg DM. Baboon anti-idiotype antibodies mimic a carcinoembryonic antigen epitope. Int J Cancer 1990; 46:310–314.PubMedCrossRefGoogle Scholar
  18. 18.
    Losman MJ, Hansen HJ, Sharkey RM, Goldenberg DM, Monestier M. Human response against NP-4, a mouse antibody to carcinoembryonic antigen: human anti-idiotype antibodies mimic an epitope on the tumor antiaen. Proc Natl Acad Sci USA 1991; 88:3421–3425.PubMedCrossRefGoogle Scholar
  19. 19.
    Losman MJ, Novick KE, Goldenberg DM, Monestier M. Mimicry of a carcinoembryonic antigen epitope by a rat monoclonal anti-idiotype antibody. Int J Cancer 1994; 56:580–584.PubMedCrossRefGoogle Scholar
  20. 20.
    Tsujisaki M, Imai K, Tokuchi S, Hanzawa Y, Ishida T, Kitagawa H, et al. Induction of antigen-specific immune response with use of anti-idiotypic monoclonal antibodies to anti-carcinoembryonic antigen antibodies. Cancer Res 1991; 51:2599–2604.PubMedGoogle Scholar
  21. 21.
    Durrant LG, Denton GW, Jacobs E, Mee M, Moss R, Austin EB, et al. An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumours. Int J Cancer 1992; 50:811–816.PubMedCrossRefGoogle Scholar
  22. 22.
    de Moraes JZ, Carneiro CR, Buchegger F, Mach JP, Lopes JD. Induction of an immune response through the idiotypic network with monoclonal anti-idiotype antibodies in the carcinoembryonic antigen system. J Cell Biochem 1992; 50:324–335.PubMedCrossRefGoogle Scholar
  23. 23.
    Gaida Fi, Fenger U, Wagener C, Neumaier M. A monoclonal anti-idiotypic antibody bearing the image of an epitope specific to the human carcinoembryonic antigen. Int J Cancer 1992; 51:459–465.CrossRefGoogle Scholar
  24. 24.
    Chatterjee SK, Tripathi PK, Chakraborty M, Yannelli J, Wang H, Foon KA, et al. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody. Cancer Res 1998; 58:1217–1224.PubMedGoogle Scholar
  25. 25.
    Bhattachary-Chatterjee M, Nath Bara! R, Chatterjee SK, Das R, Zeytin H, Chakraborty M, et al. Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine. Cancer Immunol Immunother 2000; 49:133–141.PubMedCrossRefGoogle Scholar
  26. 26.
    Staib L, Birebent B, Somasundaram R, Purev E, Braumuller H, Leeser C, et al. Immunogenicity of recombinant GA733–2E antigen (C017–1A, EGP, KS1–4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients. Int J Cancer 2001; 92:79–87.PubMedCrossRefGoogle Scholar
  27. 27.
    Herlyn D, Wettendorff M, Schmoll E, Iliopoulos D, Schedel I, Dreikhausen U, et al. Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc Nat! Acad Sci USA 1987; 84:8055–8059.PubMedCrossRefGoogle Scholar
  28. 28.
    Birebent B, Koido T, Mitchell E, Li W, Somasundaram R, Purev E, et al. Anti-idiotypic antibody (ab2) vaccines: coupling of Ab2 BR3E4 to KLH increases humoral and/or cellular immune responses in animals and colorectal cancer patients. J Cancer Res Clin Oncol 2001; 127(Suppl 2):R27-R33.CrossRefGoogle Scholar
  29. 29.
    Fagerberg J, Steinitz M, Wigzell H, Askelof P, Mellstedt H. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Nat. Acad Sci USA 1995; 92:4773–4777.PubMedCrossRefGoogle Scholar
  30. 30.
    Austin EB, Robins RA, Durrant LG, Price MR, Baldwin RW. Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36. Immunology 1989; 67:525–530.PubMedGoogle Scholar
  31. 31.
    Li L, Spendlove I, Morgan J, Durrant LG. CD55 is over-expressed in the tumour environment. Br J Cancer 2001; 84:80–86.PubMedCrossRefGoogle Scholar
  32. 32.
    Maxwell-Armstrong CA, Durrant LG, Buckley TJ, Scholefield JH, Robins RA, Fielding K, et al. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br J Cancer 2001; 84:1443–1446.PubMedCrossRefGoogle Scholar
  33. 33.
    Mittelman A, Chen ZJ, Kageshita T, Yang H, Yamada M, Baskind P, et al. Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies. J Clin Invest 1990; 86:2136–2144.PubMedCrossRefGoogle Scholar
  34. 34.
    Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanomaassociated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2–23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 1992; 89:466–470.PubMedCrossRefGoogle Scholar
  35. 35.
    Quan WD, Jr, Dean GE, Spears L, Spears CP, Groshen S, Merritt JA, et al. Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase MI trial of I-Mel-2 plus SAF-m. J Clin Oncol 1997; 15:2103–2110.PubMedGoogle Scholar
  36. 36.
    Hamilton WB, Helling F, Lloyd KO, Livingston PO. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer 1993; 53:566–573.PubMedCrossRefGoogle Scholar
  37. 37.
    Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL. Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 1985; 35:607–612.PubMedCrossRefGoogle Scholar
  38. 38.
    Sen G, Chakraborty M, Foon KA, Reisfeld RA, Bhattacharya-Chatterjee M. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2. Clin Cancer Res 1997; 3:1969–1976.PubMedGoogle Scholar
  39. 39.
    Chapman PB, Houghton AN. Induction of IgG antibodies against GD3 ganglioside in rabbits by an antiidiotypic monoclonal antibody. J Clin Invest 1991; 88:186–192.PubMedCrossRefGoogle Scholar
  40. 40.
    Yao TJ, Meyers M, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res 1999; 5:77–81.PubMedGoogle Scholar
  41. 41.
    Yamamoto S, Yamamoto T, Saxton RE, Hoon DS, Irie RF. Anti-idiotype monoclonal antibody carrying the internal image of ganglioside GM3. J Natl Cancer Inst 1990: 82:1757–1760.PubMedCrossRefGoogle Scholar
  42. 42.
    Schlebusch H, Wagner U, Grunn U, Schultes B. A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor- associated antigen CA 125 for immunotherapy of ovarian cancer. Hybridoma 1995; 14:167–174.PubMedCrossRefGoogle Scholar
  43. 43.
    Wagner U, Kohler S, Reinartz S, Giffels P, Huober J, Renke K, et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. See the biology behind: K. A. Foon and M. Bhattacharya-Chatterjee, Are solid tumor anti-idiotype vaccines ready for prime time? Clin Cancer Res 2001; 7:1112–1115, 1154–1162.Google Scholar
  44. 44.
    Schmitt H, Khazaeli MB, Rodenburg CM, Kaul S, Bastert G. Production of mouse monoclonal antiidiotypic antibodies specific to epitopes of tumor-associated mucin TAG-12. Hybridoma 1994; 13: 389–396.PubMedCrossRefGoogle Scholar
  45. 45.
    Bhattacharya-Chatterjee M, Mrozek E, Mukerjee S, Ceriani RL, Kohler H, Foon KA. Anti-idiotype antibodies as potential therapeutic agents for human breast cancer. In: Ceriani RL, ed. Antigen and antibody molecular engineering in breast cancer diagnosis and treatment. New York: Plenum, 1994:139–148.CrossRefGoogle Scholar
  46. 46.
    Baral R, Sherrat A, Das R, Foon KA, Bhattacharya-Chatterjee M. Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu. Int J Cancer 2001; 92:88–95.PubMedCrossRefGoogle Scholar
  47. 47.
    Hsu PL, Hsu SM. Identification of an Mr 70,000 antigen associated with Reed-Sternberg cells and interdigitating reticulum cells. Cancer Res 1990; 50:350–357.PubMedGoogle Scholar
  48. 48.
    Schobert I, Renner C, Pfreundschuh M, Diehl V, Pohl C. Mimicry of the Hodgkin-associated IRAC antigen by an anti-idiotype network: potential use in active immunotherapy of Hodgkin’ s lymphoma. Leuk Lymphoma 1994; 13:429–440.PubMedCrossRefGoogle Scholar
  49. 49.
    Bhattacharya-Chatterjee M, Chatterjee SK, Vasile S, Seon BK, Kohler H. Idiotype vaccines against human T cell leukemia. II. Generation and characterization of a monoclonal idiotype cascade (Ab1, Ab2, and Ab3). J Immunol 1988; 141:1398–1403.PubMedGoogle Scholar
  50. 50.
    Foon KA, Oseroff AR, Vaickus L, Greenberg SJ, Russell D, Bernstein Z, et al. Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen. Clin Cancer Res 1995; 1:1285–1294.PubMedGoogle Scholar
  51. 51.
    Huston JS, Geoge AJT, Tai MS, McCartney JE, Jin D, Segal DM, et al. Single-chain Fy design and production by preparative folding. In: Borrebaeck CAK, ed. Antibody engineering, 2nd ed. New York: Oxford University Press, 1995:185–227.Google Scholar
  52. 52.
    Tripathi PK, Qin H, Deng S, Xu C, Bhattacharya-Chatterjee M, Foon KA, et al. Antigen mimicry by an anti-idiotypic antibody single chain variable fragment. Mol Immunol 1998; 35:853–863.PubMedCrossRefGoogle Scholar
  53. 53.
    Reinartz S, Wagner U, Giffels P, Gruenn U, Schlebusch H, Wallwiener D. Immunological properties of a single-chain fragment of the anti-idiotypic antibody ACA125. Cancer Immunol Immunother 2000; 49:186–192.PubMedCrossRefGoogle Scholar
  54. 54.
    Sen G, Chakraborty M, Foon KA, Reisfeld RA, Bhattacharya-Chatterjee M. Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2. J Immunother 1998: 21:75–83.PubMedCrossRefGoogle Scholar
  55. 55.
    Foon KA, Sen G, Hutchins L, Kashala OL, Baral R, Banerjee M, et al. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin Cancer Res 1998; 4:1117–1124.PubMedGoogle Scholar
  56. 56.
    Zeytin HE, Tripathi PK, Bhattacharya-Chatterjee M, Foon KA, Chatterjee SK. Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2. Cancer Gene Ther 2000; 7:1426–1436.PubMedCrossRefGoogle Scholar
  57. 57.
    Robins RA, Denton GW, Hardcastle JD, Austin EB, Baldwin RW, Durrant LG. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody. Cancer Res 1991; 51:5425–5429.PubMedGoogle Scholar
  58. 58.
    Foon KA, Chakraborty M, John WJ, Sherratt A, Kohler H, Bhattacharya-Chatterjee M. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest 1995; 96:334–342.PubMedCrossRefGoogle Scholar
  59. 59.
    Bogen B, Weiss S. Processing and presentation of idiotypes to MHC-restricted T cells. Int Rev Immunol 1993: 10:337–355.PubMedCrossRefGoogle Scholar
  60. 60.
    Coffman RL, Seymour BW, Lebman DA, Hiraki DD, Christiansen JA, Shrader B, et al. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol Rev 1988; 102:5–28.PubMedCrossRefGoogle Scholar
  61. 61.
    Weiss S, Bogen B. MHC class II-restricted presentation of intracellular antigen. Cell 1991; 64:767–776.PubMedCrossRefGoogle Scholar
  62. 62.
    Austin EB, Robins RA, Baldwin RW, Durrant LG. Induction of delayed hypersensitivity to human tumor cells with a human monoclonal anti-idiotypic antibody. J Natl Cancer Inst 1991; 83:1245–1248.PubMedCrossRefGoogle Scholar
  63. 63.
    Chen ZJ, Yang H, Ferrone S. Human high molecular weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody MK2–23. Characterization of the immunogenicity in syngeneic hosts. J Immunol 1991; 147:1082–1090.PubMedGoogle Scholar
  64. 64.
    Lee VK, Harriott TG, Kuchroo VK, Halliday WJ, Hellstrom I, Hellstrom KE. Monoclonal antiidiotypic antibodies related to a murine oncofetal bladder tumor antigen induce specific cell-mediated tumor immunity. Proc Natl Acad Sci USA 1985; 82:6286–6290.PubMedCrossRefGoogle Scholar
  65. 65.
    Uemura H, Okajima E, Debruyne FM, Oosterwijk E. Immunization with anti-idiotype monoclonal antibodies bearing the internal image of the renal-cell carcinoma-associated antigen G250 induces specific cellular immune responses. Int J Cancer 1994; 59:802–807.PubMedCrossRefGoogle Scholar
  66. 66.
    Herlyn D, Harris D, Zaloudik J, Sperlagh M, Maruyama H, Jacob L, et al. Immunomodulatory activity of monoclonal anti-idiotypic antibody to anti-colorectal carcinoma antibody C017–1A in animals and patients. J Immunother Emphasis Tumor Immunol 1994; 15:303–311.PubMedCrossRefGoogle Scholar
  67. 67.
    Durrant LG, Doran M, Austin EB, Robins RA. Induction of cellular immune responses by a murine monoclonal anti-idiotypic antibody recognizing the 791Tgp72 antigen expressed on colorectal, gastric and ovarian human tumours. Int J Cancer 1995; 61:62–66.PubMedCrossRefGoogle Scholar
  68. 68.
    Chakraborty M, Mukerjee S, Foon KA, Kohler H, Ceriani RL, Bhattacharya-Chatterjee M. Induction of human breast cancer-specific antibody responses in cynomolgus monkeys by a murine monoclonal anti-idiotype antibody. Cancer Res 1995; 55:1525–1530.PubMedGoogle Scholar
  69. 69.
    Somasundaram R, Zaloudik J, Jacob L, Benden A, Sperlagh M, Hart E, et al. Induction of antigenspecific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody. J Immunol 1995; 155:3253–3261.PubMedGoogle Scholar
  70. 70.
    Foon KA, John WJ, Chakraborty M, Das R, Teitelbaum A, Garrison J, et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 1999; 17:2889–2895.PubMedGoogle Scholar
  71. 71.
    Raychaudhuri S, Saeki Y, Chen JJ, Iribe H, Fuji H, Kohler H. Tumor-specific idiotype vaccines. II. Analysis of the tumor-related network response induced by the tumor and by internal image antigens (Ab2 beta). J Immunol 1987; 139:271–278.PubMedGoogle Scholar
  72. 72.
    Ruiz PJ, Wolkowicz R, Waisman A, Hirschberg DL, Carmi P, Erez N, et al. Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nat Med 1998; 4:710–712.PubMedCrossRefGoogle Scholar
  73. 73.
    Pride MW, Shuey S, Grillo-Lopez A, Braslawsky G, Ross M, Legha SS, et al. Enhancement of cellmediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen. Clin Cancer Res 1998; 49 363–9370Google Scholar
  74. 74.
    Durrant LG, Buckley TJ, Denton GW, Hardcastle JD, Sewell HF, Robins RA. Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7. Cancer Res 1994: 54:4837–4840.PubMedGoogle Scholar
  75. 75.
    Raychaudhuri S, Kang CY, Kaveri SV, Kieber-Emmons T, Kohler H. Tumor idiotype vaccines. VII. Analysis and correlation of structural, idiotypic, and biologic properties of protective and nonprotective Ab2. J Immunol 1990; 145:760–767.PubMedGoogle Scholar
  76. 76.
    Bona CA. Idiotype vaccines: forgotten but not gone. Nat Med 1998; 4:668–669.PubMedCrossRefGoogle Scholar
  77. 77.
    Foon KA, Bhattacharya-Chatterjee M. Idiotype vaccines in the clinic. Nat Med 1998; 4:870.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2004

Authors and Affiliations

  • Sunil K. Chatterjee
  • Malaya Bhattacharya-Chatterjee
  • Kenneth A. Foon

There are no affiliations available

Personalised recommendations